Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,659
datasets available to search
ShareScore release 0.9.0
Dataset results
1,659 results for “Patient Data”
Patient data
Open the record for dataset details and reuse information.
Data for: Communicating with deaf patients in the clinical environment: Lessons learned from a virtual patient panel
Open the record for dataset details and reuse information.
Patients' raw data for rapid physical exam method
Open the record for dataset details and reuse information.
ESMO-GROW checklist for the publication PD-1/PD-L1 blockade plus abnobaViscum® therapy is associated with improved survival in advanced or metastasized NSCLC patients, a real-world data registry study according to the ESMO-GROW criteria
Open the record for dataset details and reuse information.
Data of patients
Open the record for dataset details and reuse information.
Data from: Analysis and prediction of effects of the Manchester Triage System on patient waiting times in an emergency department by means of agent-based simulation
A simulation of complex clinical processes is a challenging task and suitable methods need to be found which can capture the influence of relevant factors and their relationships. The Manchester triage system (MTS) is widely used in German emergency departments (ED), however the impact on patient waiting times remain difficult to predict. The purpose of this work is the assessment of MTS particularly with regard to the waiting times of different degrees of severity. The methodology of agent based simulation was found suitable for the ED domain and the agent based simulation tool SeSAm was chosen due to its intuitive user interface and easy adaption of the simulation models. Altogether four agent classes could be implemented based on the information derived from a process model. The model permits a dynamic simulation of the ED processes and a reliable assessment of patient waiting times. In addition, the implementation of a triage nurse allowed the simulation of the triage process and a direct comparison to the current state without a standardized triage procedure. Essential influencing factors (e.g. number of patients, manning level) were implemented and their effects on the ED processes and patient waiting times assessed. The simulation runs delivered correct results based on the underlying process model and the collected statistical data. The process flow and the waiting times of an ED could be mapped exactly. In all simulation runs the waiting times of high triage levels (MTS-levels 1 and 2) could be reduced. Especially patients of MTS-level 2 in the waiting area of the ED benefit significantly from the implementation of a standardized triage procedure and the associated permanent monitoring.
Data from: Age of heart disease presentation and dysmorphic nuclei in patients with LMNA mutations
Nuclear shape defects are a distinguishing characteristic in laminopathies, cancers, and other pathologies. Correlating these defects to the symptoms, mechanisms, and progression of disease requires unbiased, quantitative, and high-throughput means of quantifying nuclear morphology. To accomplish this, we developed a method of automatically segmenting fluorescently stained nuclei in 2D microscopy images and then classifying them as normal or dysmorphic based on three geometric features of the nucleus using a package of Matlab codes. As a test case, cultured skin-fibroblast nuclei of individuals possessing LMNA splice-site mutation (c.357-2A>G), LMNA nonsense mutation (c.736 C>T, pQ246X) in exon 4, LMNA missense mutation (c.1003C>T, pR335W) in exon 6, Hutchinson-Gilford Progeria Syndrome, and no LMNA mutations were analyzed. For each cell type, the percentage of dysmorphic nuclei, and other morphological features such as average nuclear area and average eccentricity were obtained. Compared to blind observers, our procedure implemented in Matlab codes possessed similar accuracy to manual counting of dysmorphic nuclei while being significantly more consistent. The automatic quantification of nuclear defects revealed a correlation between in vitro results and age of patients for initial symptom onset. Our results demonstrate the method's utility in experimental studies of diseases affecting nuclear shape through automated, unbiased, and accurate identification of dysmorphic nuclei.
Data from: Can recombinant human thrombomodulin increase survival among patients with severe septic-induced disseminated intravascular coagulation: a single-centre, open-label, randomised controlled trial
Objective: To determine whether treatment with recombinant human thrombomodulin (rhTM) increases survival among severe septic patients with sepsis-induced disseminated intravascular coagulation (DIC) Design: Single-center, open-label, randomized controlled trial Setting: Single tertiary hospital Participant: 92 severe septic patients with sepsis-induced DIC Interventions: Patients with DIC scores ≥4, as defined by the Japanese Association of Acute Medicine, were diagnosed with DIC. Randomization was performed by the envelope method. The treatment group (rhTM group, n = 47) was intravenously treated with rhTM within 24 h of admission (day 0), and the control group (n = 45) did not receive any anti-coagulants, except in cases of deep venous thrombosis and pulmonary embolism. Primary and secondary measurements: Data were collected on days 0 (admission), 1, 2, 3, 5, 7, and 10. The primary outcome was survival at 28 and 90 days. The secondary endpoints comprised changes in DIC scores, platelet counts, D-dimer, antithrombin III (ATIII), and C-reactive protein (CRP) levels, and Sequential Organ Failure Assessment (SOFA) scores. All analyses were conducted on an intent-to-treat basis. Main Results: The 28-day survival rates were 84 and 83% in the control and rhTM groups, respectively (p = 0.745, log rank test). The 90-day survival rates were 73% and 72% in the control and rhTM groups, respectively (p = 0.94, log rank test). Meanwhile, the rates of recovery from DIC (<4) were significantly higher in the rhTM group than in the control group (p = 0.001, log rank test). Relative change from baseline of D-dimer levels were significantly lower in the rhTM group than in the control group, on day 3 and 5. Conclusion: rhTM treatment decreased D-dimer levels and facilitated DIC recovery in severe septic patients with sepsis-induced DIC. However, the treatment did not improve survival in this cohort.
Data from: Can perfusion CT unmask postictal stroke mimics? A case-control study of 133 patients
OBJECTIVE: To study the diagnostic value of volume perfusion CT (VPCT) in patients with transient focal neurological deficits following and during epileptic seizures, that mimic symptoms of stroke. METHODS: a retrospective case-control study was performed on 159 patients that presented with a seizure and received an emergency VPCT within the first 3.5 hours of admission, after being misjudged to have an acute stroke. The reference test was a clinical-based, EEG-supported diagnostic algorithm for seizure. RESULTS: We included 133 patients: 94 stroke-mimicking cases with postictal focal neurological deficits ("Todd's phenomenon", n=67) or ongoing seizure on hospital admission ("ictal patients", n=27), and 39 postictal controls without focal neurological deficits. Patients with Todd's phenomenon showed normal (64%), hypo (21%)- and hyperperfusion (14%) on early VPCT. Ictal patients displayed more hyperperfusion compared to postictal patients (p=0.015). Test sensitivity of hyperperfusion for ictal patients is 38% CI [20.7-57.7], specificity 86% CI [77.3-91.7], positive predictive value (ppv) is 42% CI [27.5-58.7], the negative predictive value (npv) 83% CI [78.6-86.9]. A cortical distribution was seen in all hyperperfusion scans, compared to a cortico-subcortical pattern in hypoperfusion (p<0.001). A history of complex focal seizure and age were associated with hyperperfusion (p= 0.046 and 0.038, respectively). CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that VPCT accurately differentiates ictal stroke mimics from acute ischemic stroke. CONCLUSION: VPCT can differentiate ictal stroke mimics with hyperperfusion from acute ischemic stroke, but not postictal patients who display perfusion patterns overlapping with ischemic stroke.
Data from: Association of CSF Orexin-A levels and nocturnal sleep stability in patients with hypersomnolence
<p><span><b>Objective: </b>To evaluate the associations between cerebrospinal fluid orexin-A (ORX) levels and markers of nocturnal sleep stability, assessed by polysomnography (PSG).</span></p> <p><span><b>Methods: </b>Nocturnal PSG data and ORX levels of 300 drug-free subjects (55% men, 29.9±15.5 years, ORX level 155.1±153.7 pg/ml) with hypersomnolence were collected. Several markers of nocturnal sleep stability were analyzed: wake and sleep bouts, sleep/wake transitions. Groups were categorized according to ORX levels, in two categories (deficient≤110; >110), in tertiles (≤26, ]26;254], >254), and compared using logistic regression models. Results were adjusted for age, sex and body mass index.</span></p> <p class="MsoCommentText"><span><b>Results: </b>We found higher<b> </b>number of wake bouts (43 vs 25, p<0.0001), sleep bouts (43 vs 25.5, p<0.0001) and index of sleep bouts/hour of sleep time, but lower index of wake bouts/hour of waketime (41.4 vs 50.6, p<0.0001) in subjects with ORX deficiency. The percentage of wake bouts <30sec was lower (51.3 vs 60.8%, p<0.001) and of wake bouts ³1min30sec higher (7.7 vs 6.7%, p=0.02) when ORX deficient. The percentage of sleep bouts ≤14min was higher (2-5min: 23.7 vs 16.1%, p<0.0001), and of long sleep bouts lower (>32min30sec: 7.3 vs 18.3%, p<0.0001) when ORX deficient. These findings were confirmed when groups were categorized according to ORX tertiles, with a dose-response effect of ORX levels in post-hoc comparisons, and in adjusted models.</span></p> <p><span><b>Interpretation: </b>This study shows an association between ORX levels and nocturnal sleep stabilization in patients with hypersomnolence. Sleep and wake bouts are reliable markers of nighttime sleep stability that correlate with CSF ORX levels in a dose-dependent manner.</span></p>
SKIRT data (1945 patients)
<p>- Basic information of the 1945 patients</p> <p>- Two-dimensional embedding of the 11150 immune profiles</p>
Raw Data for the article: Permanent pacemaker implantation after valve and arrhythmia surgery in patients with preoperative atrial fibrillation
<p><strong>Background: </strong>Among patients referred for cardiac surgery, atrial fibrillation (AF) is a common comorbidity and a risk factor for postoperative arrhythmias (eg, sinus node dysfunction, atrioventricular heart block), including those requiring permanent pacemaker (PPM) implantation.</p> <p><strong>Objective: </strong>The purpose of this study was to evaluate the prevalence and long-term survival of postoperative PPM implantation in patients with preoperative AF who underwent valve surgery with or without concomitant procedures.</p> <p><strong>Methods: </strong>Presented analysis pertains to the HEIST (HEart surgery In atrial fibrillation and Supraventricular Tachycardia) registry. During the study period, 11,949 patients underwent valvular (aortic, mitral, or tricuspid valve replacement or repair) surgery and/or surgical ablation (SA) and were stratified according to postoperative PPM status.</p> <p><strong>Results: </strong>PPM implantation after surgery was necessary in 2.5% of patients, with significant variation depending on the type of surgery (from 1.1% in mitral valve repair to 3.3% in combined mitral and tricuspid valve surgery). In a multivariate logistic regression model, tricuspid intervention (P <.001), cardiopulmonary bypass time (P = .024), and endocarditis (P = .014) were shown to be risk factors for PPM. Over long-term follow-up, PPM was not associated with increased mortality compared to no PPM (hazard ratio 0.96; 95% confidence interval 0.77-1.19; P = .679). SA was not associated with PPM implantation. However, SA improved survival regardless of PPM status (log rank P <.001).</p> <p><strong>Conclusion: </strong>In patients with preoperative AF, the need for PPM implantation after valve surgery or SA is not an infrequent outcome, with SA not affecting its prevalence but actually improving long-term survival.</p>
Data of patients with organophosphate pesticide poisoning.
<p>This is the data of patients with organophosphate pesticide poisoning.</p>
Study to Collect Data on Fabry Disease Patients With Enhanceable Alpha-Galactosidase A Activity
ClinicalTrials.gov study NCT00106912. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Clinical Characteristics and Prognosis of STEMI Patients Undergoing Primary Percutaneous Coronary Angioplasty and Angiographic Data
ClinicalTrials.gov study NCT05679843. IPD Sharing: NO. Countries: 0. Publications: 1.
An Additional Analysis of Data From the PARADIGM Exploratory Study (NCT02394834) in Patients With Advanced/Recurrent Colorectal Cancer
ClinicalTrials.gov study NCT05030493. IPD Sharing: YES. Countries: 1. Publications: 0.
Initial Severity and Antidepressant Efficacy for Anxiety Disorders: an Individual Patient Data Meta-analysis
ClinicalTrials.gov study NCT02476136. IPD Sharing: NO. Countries: 0. Publications: 1.
Results Of Patient Rated Asthma Control Test In Comparison To Diary Card Data
ClinicalTrials.gov study NCT00363480. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Study Based on Health Insurance Data About the Treatment of Patients Who Have Been Newly Diagnosed With Chronic Obstructive Pulmonary Disease (COPD)
ClinicalTrials.gov study NCT04097223. IPD Sharing: NO. Countries: 1. Publications: 0.
Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry on a Cohort of Patients Receiving Plerixafor
ClinicalTrials.gov study NCT01362972. IPD Sharing: Not stated. Countries: 0. Publications: 3.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.